Bellmunt Molins, Joaquim, 1959-Selvarajah, ShaminiRodig, ScottSalido Galeote, MartaMuga, Silvia deCosta, IrmgardBellosillo Paricio, BeatrizWerner, LillianMullane, Stephanie A.Fay, André P.O’Brien, RobertBarretina, JordiMinoche, André E.Signoretti, SabinaMontagut Viladot, ClaraHimmelbauer, HeinzBerman, David M.Kantoff, PhilipChoueiri, Toni K.Rosenberg, Jonathan E.2023-06-272023-06-272014Bellmunt J, Selvarajah S, Rodig S, Salido M, de Muga S, Costa I, et al. Identification of ALK gene alterations in urothelial carcinoma. PLoS ONE. 2014 Aug 1;9(8):e103325. DOI: 10.1371/journal.pone.01033251932-6203http://hdl.handle.net/10230/57365Includes supplementary materials for the online appendix.Includes supplementary materials for the online appendix.Anaplastic lymphoma kinase (ALK) genomic alterations have emerged as a potent predictor of benefit from treatment with ALK inhibitors in several cancers. Currently, there is no information about ALK gene alterations in urothelial carcinoma (UC) and its correlation with clinical or pathologic features and outcome. Samples from patients with advanced UC and correlative clinical data were collected. Genomic imbalances were investigated by array comparative genomic hybridization (aCGH). ALK gene status was evaluated by fluorescence in situ hybridization (FISH). ALK expression was assessed by immunohistochemistry (IHC) and high-throughput mutation analysis with Oncomap 3 platform. Next generation sequencing was performed using Illumina Genome Analyzer IIx, and Illumina HiSeq 2000 in the FISH positive case. 70 of 96 patients had tissue available for all the tests performed. Arm level copy number gains at chromosome 2 were identified in 17 (24%) patients. Minor copy number alterations (CNAs) in the proximity of ALK locus were found in 3 patients by aCGH. By FISH analysis, one of these samples had a deletion of the 5′ALK. Whole genome next generation sequencing was inconclusive to confirm the deletion at the level of the ALK gene at the coverage level used. We did not observe an association between ALK CNA and overall survival, ECOG PS, or development of visceral disease. ALK genomic alterations are rare and probably without prognostic implications in UC. The potential for testing ALK inhibitors in UC merits further investigation but might be restricted to the identification of an enriched population.application/pdfeng© 2014 Bellmunt et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Càncer -- TractamentCòlon -- CàncerTumorsinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1371/journal.pone.0103325info:eu-repo/semantics/openAccess